All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a healthcare professional. If you are a patient or carer, please visit the Lymphoma Coalition.
The Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Lymphoma & CLL Hub is an independent medical education platform, sponsored by AbbVie, BeOne Medicines, Miltenyi Biomedicine, Nurix Therapeutics, Roche, Sobi, and Thermo Fisher Scientific and supported through educational grants from Bristol Myers Squibb, Eli Lilly, and Pfizer. Funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View lymphoma & CLL content recommended for you
Gazyvaro® (obinutuzumab) in combination with chemotherapy approved by the EMA for the treatment of newly diagnosed Follicular Lymphoma
On 22nd September 2017, the European Medicines Agency (EMA) approved Gazyvaro® (obinutuzumab) in combination with chemotherapy and followed by Gazyvaro® maintenance in patients achieving a response to treat newly diagnosed Follicular Lymphoma (FL).
The approval of Roche’s anti-CD20 monoclonal antibody is based on results of the phase III GALLIUM study (NCT01332968), the first trial in newly diagnosed FL to demonstrate superior PFS compared to rituximab based therapy, and follows a ‘positive opinion’ given by the EMA’s Committee for Medicinal Products for Human Use (CHMP) in July 2017 (read more here).
This is the third EMA approval for Gazyvaro®: in 2014 it was approved in combination with chlorambucil for patients newly diagnosed Chronic Lymphocytic Leukaemia (CLL) with comorbidities and unsuited to full-dose fludarabine-based therapy; and in June 2016, Gazyvaro® received approval in combination with bendamustine, followed by Gazyvaro® maintenance, in FL patients who did not respond or who progressed ≤6 months after receiving rituximab-based therapy.
References
Please indicate your level of agreement with the following statements:
The content was clear and easy to understand
The content addressed the learning objectives
The content was relevant to my practice
I will change my clinical practice as a result of this content
Your opinion matters
In your experience, what is the average vein-to-vein time when treating patients with DLBCL with a reimbursed CAR T-cell therapy (from apheresis to infusion)?